Safety of buprenorphine transdermal system in the management of pain in older adults

被引:14
|
作者
Pergolizzi, Joseph V. [1 ,2 ]
Raffa, Robert B. [3 ,4 ]
Marcum, Zachary [5 ]
Colucci, Salvatore [6 ]
Ripa, Steven R. [6 ]
机构
[1] Naples Anesthesia & Pain Associates, Naples, FL USA
[2] NEMA Res Inc, Naples, FL USA
[3] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA
[4] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[5] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[6] Purdue Pharma LP, One Stamford Forum, Stamford, CT 06901 USA
关键词
Buprenorphine; BTDS; pain management in older adults; elderly; controlled and uncontrolled trials; 7-day transdermal formulation; geriatric pain medicine; opioid; LOW-BACK-PAIN; DOUBLE-BLIND; OPIOID ANALGESIA; ELDERLY-PATIENTS; MEDICATION USE; RISK; FALLS; FRACTURES; OSTEOARTHRITIS; MODERATE;
D O I
10.1080/00325481.2017.1270699
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To evaluate whether buprenorphine transdermal system (BTDS; Butrans (R)) is an option for the treatment of chronic pain in older adults. Methods: This retrospective analysis of 16 placebo- and active-controlled and uncontrolled studies (N = 6566) evaluated the safety and tolerability profile in patients exposed to BTDS and compared the safety profiles associated with BTDS treatment in older patients = 65 years of age (65 to 98 years) and younger patients < 65 years of age (18 to 64 years). Safety analyses included adverse events (AEs), laboratory values, and electrocardiograms. Results: Overall, the incidence of AEs was similar in the = 65 year patient cohort (N = 1715) and the < 65 year patient cohort (N = 4843) (63.8% and 61.0%, respectively). The older patient cohort experienced more constipation, peripheral edema, and urinary tract infection, but fewer application-site AEs (eg, erythema, irritation, pruritus, rash) and headaches. A statistically significant treatment-by-age interaction was observed for fall, arthralgia, and localized and non-application site-related rash, suggesting a differential increase in the risk of these events among older patients treated with BTDS that cannot be explained by age or treatment alone. A similar trend was observed for accidents and injuries, and for falls, in patients treated with both BTDS and active controls (oxycodone/acetaminophen [OXY/APAP] and hydrocodone/acetaminophen [HCD/APAP]), suggesting an opioid class effect. However, due to small sample sizes of the active control groups, a statistical test of treatment-by-age interaction could not be conducted for the active controls. The incidences of serious AEs and of clinically significant increases in liver enzymes, such as AST, ALT and bilirubin were small, regardless of age. Conclusion: BTDS appears to be a viable option for the management of pain in older adults, but the benefits need to be tempered by potential risks among older adults.
引用
收藏
页码:92 / 101
页数:10
相关论文
共 50 条
  • [41] Buprenorphine and Cardiac Surgery: Navigating the Challenges of Pain Management
    Fernando, Rohesh J.
    Graulein, Derrick
    Hamzi, Rawad I.
    Augoustides, John G.
    Khalil, Suzana
    Sanders, Joseph
    Sibai, Nabil
    Hong, Tracey S.
    Kiwakyou, Larissa M.
    Brodt, Jessica L.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2022, 36 (09) : 3701 - 3708
  • [42] US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system
    Pergolizzi, Joseph V., Jr.
    Ben-Joseph, Rami
    Chang, Chun-Lan
    Hess, Gregory
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1579 - 1587
  • [43] Overview of Pain Management in Older Adults
    Savvas, Steven M.
    Gibson, Stephen J.
    CLINICS IN GERIATRIC MEDICINE, 2016, 32 (04) : 635 - +
  • [44] Persistent Pain Management in Older Adults
    Arnstein, Paul
    Herr, Keela A.
    JOURNAL OF GERONTOLOGICAL NURSING, 2017, 43 (07): : 20 - 31
  • [45] Management of chronic pain in older adults
    Reid, M. Carrington
    Eccleston, Christopher
    Pillemer, Karl
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [46] The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus
    Pergolizzi, Joseph V., Jr.
    Mercadante, Sebastiano
    Virizuela Echaburu, Antonio
    Van den Eynden, Bart
    de Faria Fragoso, Rosa Maria
    Mordarski, Sylvester
    Lybaert, Willem
    Beniak, Juraj
    Oronska, Anna
    Slama, Ondrej
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (06) : 1517 - 1528
  • [47] Efficacy and Safety of Transdermal Buprenorphine for Acute Postoperative Pain: A Systematic Review and Meta-analysis
    Aguilar, Brydget
    Penm, Jonathan
    Liu, Shania
    Patanwala, Asad E.
    JOURNAL OF PAIN, 2023, 24 (11): : 1905 - 1914
  • [48] Managing Cancer Pain in Older Adults
    Guerard, Emily J.
    Cleary, James F.
    CANCER JOURNAL, 2017, 23 (04): : 242 - 245
  • [49] Buprenorphine for neuropathic pain in adults
    Wiffen, Philip J.
    Derry, Sheena
    Moore, R. Andrew
    Stannard, Cathy
    Aldington, Dominic
    Cole, Peter
    Knaggs, Roger
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [50] The application of transdermal buprenorphine in the treatment of chronic cancer pain
    Cialkowska-Rysz, Aleksandra
    Kazmierczak-Lukaszewicz, Sylwia
    Gottwald, Leszek
    MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2009, 1 (01): : 40 - 44